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Sensitivity analysis confirmed the robustness of the model findings. 
CONCLUSIONS: This study shows that in Argentina, according to the model cost-
effectiveness results, abatacept with MTX would be dominant treatment option 
compared to infliximab and tocilizumab, for patients with rheumatoid arthritis 
after an inadequate response to MTX.  
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OBJECTIVES: Approximately 0.4% of the Latin American population over 16 years 
old is affected by Rheumatoid Arthritis (RA). RA has an important economic and 
social impact due to its chronic and progressive condition. The objective is to 
assess the cost-effectiveness (CE) of etanercept in the treatment for moderate to 
severe RA, among patients failing antirheumatic drugs, in comparison with the 
rest of anti-TNF and IL-6 blockers available in Honduras, from the health care 
payer’s perspective. METHODS: A decision-tree model was implemented to 
compare the costs and effectiveness of etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate, in the treatment of RA in adult population of Honduras. The 
effectiveness measures were: American College of Rheumatology (ACR) Response 
Criteria ACR<20 and ACR<70. Quality utilities were obtained from Health 
Assessment Questionnaire (HAQ). Local costs (2012 US$) were obtained from 
Official Social Security databases of Honduras. The outcomes were: total costs of 
RA (adverse events, exams and treatments) and QALYs gained. Univariate 
sensitivity analysis was performed. The time horizon was 2 years and the 
discount rate was 5% for costs and health outcomes. RESULTS: The total cost of 
etanercept was $US39,788.57, being $US1,149.43, $US3,131.82 $US6,622.29, and 
$US16,616.10 less expensive than tocilizumab, rituximab, adalimumab, and 
infliximab, respectively. Etanercept also gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Cost-effectiveness analyses showed etanercept 
as the dominant strategy. Acceptability curves showed that at the willingness-
to-pay level of US$8,000/QALY, etanercept was cost-effective with a 100% 
probability. PSA results support the robustness of these findings. CONCLUSIONS: 
This is the first CE study for RA developed in Honduran population. Etanercept 
appeared as the most cost-effective alternative for RA compared to other anti-
TNF and IL-6 blockers.  
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OBJECTIVES: Administrative claims contain detailed medication, diagnosis, and 
procedure data, but their lack of clinical outcomes for rheumatoid arthritis (RA) 
has limited their use in comparative effectiveness research. A validated claims-
based algorithm uses adherence, dosing, and treatment modifications to 
estimate biologics’ effectiveness (low disease or remission) for RA. The objective 
was to implement this algorithm in a US managed-care database and calculate 
the cost per algorithm-defined responder among biologics approved for 
moderate to severe RA (etanercept, adalimumab, infliximab, golimumab, 
abatacept). METHODS: Data were obtained from the IMS PharMetrics Plus™ 
Database, comprised of adjudicated medical and pharmaceutical claims for 150 
million unique enrollees. The cohort included patients with RA aged 18-63, 
initiating treatment between January 2007 and December 2010, without RA 
biologics 6 months before first treatment, and enrolled between 6 months before 
and 12 months after first biologic. Other TNF responsive conditions were 
excluded. The algorithm defines lack of effectiveness as: medication possession 
ratio < 80% (or fewer infusions/injections than specified on US label), increase in 
biologic dose or frequency interval, switching biologics, adding new non-biologic 
Disease Modifying Anti-Rheumatic Drugs, glucocorticoid use, initiation or 
increase of glucocorticoid dose, or > 1 parenteral or intra-articular injection 
during the follow-up period. Drug and administration costs were obtained from 
allowed amounts on claims. RESULTS: The cohort included 16,011 patients, 
mean age 49.3, 76.7% female. Algorithm effectiveness (low disease or remission) 
criteria were met in 31.0% of etanercept (n=7,247), 28.6% of adalimumab 
(n=4,991), 20.2% of infliximab (n=2,352), 28.6% of abatacept (n=1,160), and 27.2% 
of golimumab (n=261) patients in the first 12 months of treatment. Mean first 
year cost per responder was lowest for etanercept ($50,141), followed by 
golimumab ($53,386), adalimumab ($56,941), abatacept ($73,516), and infliximab 
($114,089). CONCLUSIONS: Etanercept had the highest estimated effectiveness 
and lowest cost per responder among first-line RA biologics using a new, 
validated claims-based algorithm.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 40,000 people in 
Costa Rica. It is associated with a significant effect on the patients’ quality of life 
and costs to society. The aim is to assess the cost-effectiveness of etanercept in 
the treatment for moderate to severe RA, among patients failing previous 
antirheumatic therapy (DMARDS), in comparison with the rest of anti-TNF and 
IL-6 blockers products in Costa Rica, from the health care payer’s perspective. 
METHODS: A decision tree model was used to compare the costs and 
effectiveness of the alternatives, all in combination with methotrexate, in the 
treatment of RA in adult population of Costa Rica. The alternatives included 
were: etanercept (comparator, 50mg/week), adalimumab (40mg/15 days), 
infliximab (3-10mg/kg), rituximab (1000mg day 0 and 15, week 16-24) and 
tocilizumab (8mg/kg/month). The effectiveness measures were: American 
College of Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality 
utilities were obtained from Health Assessment Questionnaire (HAQ). Local costs 
(2012 US$) were obtained from Costa Rica Social Security databases. The 
outcomes were expressed as total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was two years and the discount rate was 5% for costs and health outcomes. 
RESULTS: Results showed that etanercept gained the highest number of QALYs 
(1.5423) in comparison with adalimumab (1.5048), infliximab, (1.4299), rituximab 
(1.4674), and tocilizumab (1.4955). Etanercept appeared as the least expensive 
option (US$38,836.32) while infliximab resulted as the most expensive option 
(US$57,237.22). Cost-effectiveness analyses exhibited etanercept as the dominant 
strategy. Acceptability curves showed that at the willingness-to-pay level of 
US$10,000/QALY, Etanercept was cost-effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the most cost-effective alternative for treating RA 
among other anti-TNF and IL-6 blockers.  
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OBJECTIVES: Rheumatoid arthritis (RA) affects approximately 60.000 people in El 
Salvador. RA has a significant effect on quality of life of patients and it is 
associated with high costs to society. The objective is to assess the cost-
effectiveness (CE) of etanercept in the treatment for moderate to severe RA, 
among patients failing previous antirheumatic drugs (DMARDs), in comparison 
with the rest of anti-TNF and IL-6 blockers products available in El Salvador, 
from the health care payer’s perspective. METHODS: In order to compare the 
costs and effectiveness of the alternatives included, a decision-tree was utilized. 
The alternatives for treating RA were: etanercept (comparator, 50mg/week), 
adalimumab (40mg/15 days), infliximab (3-10mg/kg), rituximab (1000mg day 0 
and 15, week 16-24) and tocilizumab (8mg/kg/month), all in combination with 
methotrexate. The effectiveness measures were: American College of 
Rheumatology (ACR) Response Criteria ACR<20 and ACR<70. Quality utilities 
were obtained from Health Assessment Questionnaire (HAQ). Local costs (2012 
US$) were obtained from official databases from the Social Security of El 
Salvador. The outcomes were: total costs of RA and quality-adjusted life years 
(QALYs) gained. Univariate sensitivity analysis was performed. The time horizon 
was 1 year. RESULTS: Etanercept was the least expensive option ($US19,959.82) 
while infliximab was the most expensive option (US$25,262.66). The total cost for 
Adalimumab was $US21,236.14 and $21,301.85 for Rituximab. Etanercept gained 
the highest number of QALYs (0.79) compared to adalimumab (0.77), infliximab, 
(0.73), and rituximab (0.75). In the CE analyses, etanercept appeared as the 
dominant strategy. Acceptability curves showed that at the willingness-to-pay 
level of US$15,300/QALY, etanercept was cost effective with a 100% probability. 
Probability sensitivity analysis results support the robustness of these findings. 
CONCLUSIONS: Etanercept is the least expensive and most effective option for 
treating RA in El Salvador. Etanercept is cost-effective option according to <3 GDP 
per capita ($7,600; 2011) threshold of El Salvador.  
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Non-steroidal anti-inflammatory drugs (NSAIDs) are prescribed for osteoarthritis 
(OA). All NSAIDs treatment carries gastrointestinal (GI) toxicity risk, ranging from 
mild dyspepsia to GI hemorrhage and perforation. Treatment with gastric 
mucosa protectors like potassium pump inhibitors (PPI) had been associated 
with long NSAID treatment to reduce GI toxicity. OBJECTIVES: To evaluate the 
cost-effectiveness and cost-utility of fixed-dose-combination (FDC) of 
naproxen/esomeprazole, NSAIDs or cyclooxygenase-2 inhibitors’ (COX-2) in 
chronic users at risk of gastropathy. METHODS: A Markov model was developed 
with a 3-month cycle during 1 year horizon. Health states represent adverse 
events (AE) GI and cardiovascular (CV); the risk of experiencing an AE and 
moving between different health states was taken from published clinical 
research. The model estimates the net impact of the treatment alternatives 
